Knowledge & Resources
Global Innovative Contracting analysis, opinion and insights from our experts and global payer network

A payer’s perspective: Is the contracting landscape for Cell and Gene Therapies unsustainable?
In recent years, the cell and gene therapy market has been touted as a promising frontier in the pharmaceutical industry. Numerous clinical trials and regulatory approvals have driven a wave of investment and innovation. However, some analyst commentary is starting to question whether the market's early momentum has begun to wane. Despite a pipeline of nearly 400 ongoing clinical trials in Europe alone, doubts remain about whether these products will make it to market and if the recent flurry of activity is sustainable.

Announcements from South Korea (SK) to Denmark (DK) pave the way for further outcomes-based contracting for high-cost oncology drugs
Multi-indication and combination therapies are rapidly influencing the oncology marketplace. Faced with increasing treatment complexity and budget demands, payers across the globe are starting to evolve their approach to contracting.